Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 12,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Treatment with Placebo Clear all

Conditions: Psoriasis
Interventions: Etanercept, Placebo injections; Biological · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Irvine, California • Winston-Salem, North Carolina • Seattle, Washington

Conditions: Sickle Cell Disease
Interventions: ICA-17043; Drug
Lead sponsor: Icagen; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 42
States / cities: Mobile, Alabama • Little Rock, Arkansas • Davis, California + 39 more

Conditions: Prader-Willi Syndrome, Hyperphagia
Interventions: Intranasal Oxytocin (IN-OXT), Matched Placebo; Drug · Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 5 Years to 18 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Cocaine Abuse, Cocaine-Related Disorders
Interventions: Modafinil, Levodopa/Carbidopa, Naltrexone HCl, Placebo, Motivational Interviewing (MI), Contingency management (CM), Cognitive-Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 55 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aging, Balance Deficits
Interventions: Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham; Device
Lead sponsor: Weinberg Medical Physics LLC; Industry
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: FSGS
Interventions: DMX-200, Placebo; Drug
Lead sponsor: Dimerix Bioscience Pty Ltd; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 54
States / cities: Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 44 more

Conditions: Brain Injuries
Interventions: CDP-Choline, Placebo; Drug
Lead sponsor: Patricia M. Arenth; Other
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
Interventions: Nelotanserin, Placebo; Drug
Lead sponsor: Axovant Sciences Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 20 more

Conditions: Pain, Inflammation
Interventions: bromfenac ophthalmic solution, placebo comparator; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Irvine, California

Conditions: Bilateral Nasal Polyposis
Interventions: Fluticasone propionate; Drug
Lead sponsor: Optinose US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 10
States / cities: Stockton, California • Centennial, Colorado • Louisville, Kentucky + 7 more

Conditions: Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions: Standard care, Metformin, Placebo; Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 20 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hyperlipidemias
Interventions: Lapaquistat acetate and fenofibrate, Fenofibrate; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 32
States / cities: Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more

Conditions: Generalized Anxiety Disorder (GAD)
Interventions: EXOMIND (BTL-699-2) Active treatment, EXOMIND (BTL-699-2) Sham treatment; Device
Lead sponsor: BTL Industries Ltd.; Industry
Eligibility: 22 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Denver, Colorado • Chicago, Illinois • Newburgh, Indiana

Conditions: Kawasaki Disease
Interventions: Infliximab, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 4 Weeks to 17 Years
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: La Jolla, California • Columbus, Ohio

Conditions: Osteoarthritis
Interventions: celecoxib, Oxycodone, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Parkinson Disease
Interventions: Lenrispodun, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 35
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 31 more

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Ixazomib Citrate, Lenalidomide, Placebo Administration, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 221
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Arroyo Grande, California + 154 more

Conditions: Asthma
Interventions: GW685698X, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 94
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 81 more

Conditions: Atopic Dermatitis
Interventions: NM26-2198, Placebo; Biological · Other
Lead sponsor: Yellow Jersey Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Fountain Valley, California • Glendale, California • San Diego, California + 3 more

Conditions: Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic
Interventions: BIBW 2948 BS; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 5 more

Conditions: Vitamin D Deficiency
Interventions: Prenatal Vitamin, Cholecalciferol (Vitamin D3); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Major Depressive Disorder
Interventions: Agomelatine (AGO178C), Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 582 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 47
States / cities: Birmingham, Alabama • Beverly Hills, California • Encino, California + 41 more

Conditions: Overactive Bladder
Interventions: Vibegron, Placebo; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 1,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 75
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 64 more

Conditions: Asthma
Interventions: tiotropium bromide, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 5
States / cities: Denver, Colorado • Columbia, Missouri • Warrensburg, Missouri + 2 more

Search by objective public record fields.

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

A Stratified Sickle Event Randomized Trial (ASSERT)

Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

Medications for Stopping Cocaine Dependence and Preventing Relapse

Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

CDP-Choline and Working Memory After TBI: A Neuroimaging Study

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery

Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device

Metformin to Augment Low Milk Supply (MALMS) Study

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

Device for Treating Generalized Anxiety

Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

Controlled Trial of Prenatal Vitamin D3 Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants

Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma